Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 40, Issue 4, 2017, Pages 418-422

  Lewis, Stephen L ^a   Porceddu, Sandro ^b   Nakamura, Naoki ^c   Palma, David A ^d   Lo, Simon S ^e   Hoskin, Peter ^f   Moghanaki, Drew ^g   Chmura, Steven J ^h   Salama, Joseph K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f MOUNT VERNON CANCER CENTRE   (United Kingdom)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

metastasis; oligometastasis; radiation oncology; SBRT; survey

Indexed keywords

CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; EXTRACRANIAL OLIGOMETASTASIS; HUMAN; LIVER; LUNG; MAJOR CLINICAL STUDY; METASTASIS; RADIATION DOSE FRACTIONATION; RADIATION ONCOLOGIST; SPINE; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; NEOPLASM METASTASIS; PROCEDURES; QUESTIONNAIRE; RADIOSURGERY;

DOSE FRACTIONATION; HUMANS; NEOPLASM METASTASIS; RADIATION ONCOLOGISTS; RADIOSURGERY; SURVEYS AND QUESTIONNAIRES;

EID: 84922257455     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000169     Document Type: Conference Paper

References (28)

1. Timmerman R, Paulus R, Galvin J, et al. Stereotactic bodyradiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070-1076.
2. Katz AJ, Santoro M, Diblasio F, et al. Stereotactic bodyradiotherapy for localized prostate cancer: Disease control andquality of life at 6 years. Radiat Oncol. 2013;8:118.
3. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapyfor unresectable adenocarcinoma of the pancreas. Cancer. 2009;115:665-672.
4. Minn AY, Koong AC, Chang DT. Stereotactic body radiationtherapy for gastrointestinal malignancies. Front Radiat TherOncol. 2011;43:412-427.
5. McBride SM, Wagner AA, Kaplan ID. A phase 1 dose-escalationstudy of robotic radiosurgery in inoperable primary renal cellcarcinoma. Int J Radiat Oncol Biol Phys. 2013;87:S84.
6. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8-10.
7. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases:a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013;31:1384-1390.
8. Long-term results of lung metastasectomy: Prognostic analysesbased on 5206 cases The International Registry of LungMetastases. J Thorac Cardiovasc Surg. 1997;113:37-49.
9. Fong Y, Cohen AM, Fortner JG, et al. Liver resection forcolorectal metastases. J Clin Oncol. 1997;15:938-946.
10. Salama JK, Kirkpatrick JP, Yin FF. Stereotactic body radiotherapytreatment of extracranial metastases. Nature reviews. Clin Oncol. 2012;9:654-665.
11. Harris PA, Taylor R, Thielke R, et al. Research electronic datacapture (REDCap)-a metadata-driven methodology and workflowprocess for providing translational research informaticssupport. J Biomed Inform. 2009;42:377-381.
12. Moghanaki D, Urdaneta AI, Karlin JD, et al. Management ofpostprostatectomy biochemical relapse with salvage radiotherapy:results of an international survey. Am J Clin Oncol. 2014. [Epub ahead of print].
13. Mell LK, Roeske JC, Mundt AJ. A survey of intensity-modulatedradiation therapy use in the United States. Cancer. 2003;98:204-211.
14. Pan H, Simpson DR, Mell LK, et al. A survey of stereotactic bodyradiotherapy use in the United States. Cancer. 2011;117:4566-4572.
15. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, et al. Outcomes ofstereotactic ablative radiotherapy for centrally located early-stagelung cancer. J Thorac Oncol. 2011;6:2036-2043.
16. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutionalphase I/II trial of stereotactic body radiation therapy for lungmetastases. J Clin Oncol. 2009;27:1579-1584.
17. Wulf J, Baier K, Mueller G, et al. Dose-response in stereotacticirradiation of lung tumors. Radiother Oncol. 2005;77:83-87.
18. Okunieff P, Petersen AL, Philip A, et al. Stereotactic body radiationtherapy (SBRT) for lung metastases. Acta Oncol. 2006;45:808-817.
19. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutionalphase I/II trial of stereotactic body radiation therapy for livermetastases. J Clin Oncol. 2009;27:1572-1578.
20. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study ofindividualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585-1591.
21. Garg AK, Shiu AS, Yang J, et al. Phase 1/2 trial of single-sessionstereotactic body radiotherapy for previously unirradiated spinalmetastases. Cancer. 2012;118:5069-5077.
22. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiationtherapy for management of spinal metastases in patients without spinalcord compression: A phase 1-2 trial. Lancet Oncol. 2012;13:395-402.
23. Maruyama K, Yamada T, Kawakami R, et al. Randomized crossovercomparison of cervical-spine motion with the AirWay Scopeor Macintosh laryngoscope with in-line stabilization: A videofluoroscopicstudy. Br J Anaesth. 2008;101:563-567.
24. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic bodyradiotherapy for multisite extracranial oligometastases: Final reportof a dose escalation trial in patients with 1 to 5 sites of metastaticdisease. Cancer. 2012;118:2962-2970.
25. Kao J, Packer S, Vu HL, et al. Phase 1 study of concurrentsunitinib and image-guided radiotherapy followed by maintenancesunitinib for patients with oligometastases: Acute toxicity andpreliminary response. Cancer. 2009;115:3571-3580.
26. Fisher B. Laboratory and clinical research in breast cancer-apersonal adventure: The David A. Karnofsky memorial lecture. Cancer Res. 1980;40:3863-3874.
27. Keynes G. Carcinoma of the breast, the unorthodox view. ProCardiff M So. 1954;40.
28. Palma DA, Haasbeek CJ, Rodrigues GB, et al. Stereotacticablative radiotherapy for comprehensive treatment of oligometastatictumors (SABR-COMET): Study protocol for a randomizedphase II trial. BMC Cancer. 2012;12:305.